Drugs / RO7795081
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT07741604 | Sep 2026 → Feb 2028 expected | impaired renal function disease | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 1 | NCT07499050 | Mar → Dec 2026 expected | obesity disorder | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 1 | NCT06982131 | Jun 2025 → Dec 2026 expected | obesity disorder | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06809608 | Feb → May 2025 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07112872 | Aug 2025 → Feb 2028 expected | type 2 diabetes mellitus | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 2 | NCT07081958 | Jul 2025 → Apr 2026 overdue | obesity disorder | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2024-07-17 | Hoffmann-La Roche | Results [Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment of people with obesity roche.com ↗
The data showed that treatment with CT-996 in participants with obesity and without type 2 diabetes resulted in a clinically meaningful placebo-adjusted mean weight loss of -6.1% within four weeks (p <0.001). |
| 2024-07-16 | Genentech, Inc. | Results Genentech Announces Positive Phase I Results of Its Oral GLP-1 Receptor Agonist CT-996 for the Treatment of People With Obesity gene.com ↗
The data showed that treatment with CT-996 in participants with obesity and without type 2 diabetes resulted in a clinically meaningful placebo-adjusted mean weight loss of -6.1% within four weeks (p <0.001). |
All press releases naming this drug 2 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RO7795081 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07112872 ↗ |
| Route | Oral | “A single dose will be administered orally per study period (see arm descriptions).” NCT06809608 ↗ |